Avacta Group, the developer of Affimer biotherapeutics and reagents, is pleased to announce the appointment of Paul Fry as Non-Executive Director with effect from 3 February 2020.
Fry has extensive financial experience across a number of industries including biotech, pharmaceutical and telecommunications. He is currently Chief Financial Officer of Vectura Group, an inhaled drug delivery specialist listed on the FTSE Main Market.
Prior to his current position, Fry was Chief Financial Officer of Immunocore, a biotech company focused on the development of a new class of immunotherapeutic drugs based on proprietary T-cell receptor technology. Paul has also served as Director of Global Finance Operations at Vodafone plc and spent more than 25 years at GlaxoSmithKline (GSK), where he held a number of senior roles including Head of Global Finance Services and Chief Financial Officer for GSK's Italian pharmaceutical business.
PFrywill also be appointed Chair of the Audit Committee.
Commenting on his appointment, Fry said: “I am excited by the opportunity to work with Avacta in their mission to develop novel cancer immunotherapies and to commercialise the Affimer technology in other markets. I look forward to helping support the evolution of the Company and realising value for both patients and shareholders.”
